Antibody Pipeline and Out-Licensing Opportunities

Enrich your pipeline rapidly with potent antibodies, primed for clinical development

One Step Closer to the Clinic

Twist Biopharma’s antibody experts have discovered and vetted an array of lead antibodies against high-value targets, saving you the trouble of launching your discovery and optimization projects and accelerating your journey from bench to bedside.

De-Risked for Common Downstream Liabilities

Potential for First-in-Class Licensing

Evaluated by Our Experts

See Which Therapeutic Targets We’ve Unlocked

Best-in-Class Therapeutics Start With a Best-in-Class Discovery Platform

Best-in-Class Therapeutics Start With a Best-in-Class Discovery Platform

Our unique, high-quality DNA writing platform allows us to design diverse antibody variants, with base-by-base precision. Using that as our foundation, we’ve built a best-in-class discovery platform, our library of libraries, which served as the starting point for our antibody leads.

Learn More About Our Libraries

Challenging Targets Unlocked by Our Experts

Our library of libraries and internal expertise has enabled the discovery and selection of leads against challenging drug targets, like GLP-1R and ADORA2A. Each discovery project was led by our internal team of experts, with over 50 years of combined experience in therapeutic antibody development.

Challenging Targets Unlocked by Our Experts
Watch the Webinar

Watch the Webinar

Developing Therapeutics Against Virtually Any Target with New Antibody Libraries

Watch it

What Scientists Have to Say
Twist’s unique ability to generate robust, diverse and cutting-edge libraries through its proprietary silicon platform together with our deep insight into therapeutic drug discovery and development will help us expand a growing pipeline of targeted biologic candidates.
Robert Mabry
Head of Global Biologics Research, Takeda
Twist is the only synthetic DNA provider who can deliver the quantity and quality of DNA we need for our projects rapidly. We are working with them not only as a vendor for synthetic genes and antibodies, but have expanded our relationship to leverage the Twist Biopharma capabilities, which we believe complement our antibody discovery efforts.
Robert Carnahan, PhD
Associate Director of the Vanderbilt Vaccine Center